Aptose Biosciences Inc.

Posters & Presentations

All Poster Presentation
December 13, 2021 Presentation

2021 ASH Presentation - A Phase 1/2 Study of HM43239 in R/R AML

2021 ASH Presentation - A Phase 1/2 Study of HM43239 in R/R AML: View Presentation
December 11, 2021 Poster

2021 ASH Poster - A Phase 1a/b Dose Escalation Study of Luxeptinib in R/R AML

2021 ASH Poster - A Phase 1a/b Dose Escalation Study of Luxeptinib in R/R AML: View Poster
December 11, 2021 Poster

2021 ASH Poster - A Phase 1a/b Dose Escalation Study of Luxeptinib in R/R B-Cell Malignancies

2021 ASH Poster - A Phase 1a/b Dose Escalation Study of Luxeptinib in R/R B-Cell Malignancies: View Poster
June 11, 2021 Presentation

Aptose Corporate Update at EHA 2021

Aptose Corporate Update at EHA 2021: View Presentation
June 11, 2021 Poster

2021 EHA Poster - A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in R/R B-Cell Malignancies

2021 EHA Poster - A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in R/R B-Cell Malignancies: View Poster
June 11, 2021 Poster

2021 EHA Poster - A Phase 1a/b Dose Escalation Study of the MYC Repressor APTO-253 in R/R AML or HR MDS

2021 EHA Poster - A Phase 1a/b Dose Escalation Study of the MYC Repressor APTO-253 in R/R AML or HR MDS: View Poster
December 6, 2020 Presentation

Aptose Corporate Update at ASH 2020

Aptose Corporate Update at ASH 2020: View Presentation
December 6, 2020 Poster

2020 ASH Poster - A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with R/R CLL/SLL or NHL

2020 ASH Poster - A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with R/R CLL/SLL or NHL : View Poster
December 5, 2020 Poster

2020 ASH Poster - A Phase 1a/b Dose Escalation Study of the MYC Repressor APTO-253 in Patients with R/R AML or HR-MDS

2020 ASH Poster - A Phase 1a/b Dose Escalation Study of the MYC Repressor APTO-253 in Patients with R/R AML or HR-MDS: View Poster